⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVCT News
Nuvectis Pharma, Inc. Common Stock
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
globenewswire.com
NVCT
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
globenewswire.com
NVCT
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data Ready to Announce with Confidence?
newsfilecorp.com
NVCT
Form 8-K
sec.gov
NVCT
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
globenewswire.com
NVCT
Form 8-K
sec.gov
NVCT
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
globenewswire.com
NVCT
Form 8-K
sec.gov
NVCT
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
globenewswire.com
NVCT
Form 8-K
sec.gov
NVCT